Article
Carrie Printz
Expanding the Reach of TIL Therapy: What Will it Take?
Clips
Summary
Dr. Mahuron shares how tumor-infiltrating lymphocyte (TIL) therapy is evolving to reach more patients and improve cancer outcomes.
What does it take to bring tumor-infiltrating lymphocyte (TIL) therapy to more patients and make the therapy more effective for those already eligible?
In this episode of Edge of Breakthrough, Dr. Monty Pal sits down with Dr. Kelly Mahuron, a surgical oncologist at City of Hope, to unpack how TIL therapy is evolving. From identifying eligible patients and surgical harvesting of TILs to cell expansion and reinfusion, Dr. Mahuron breaks down the entire process of TIL therapy, highlighting how her cross-disciplinary team is working to improve patient outcomes, reduce toxicity, and eventually expand treatment beyond melanoma.
They also explore the next generation of TILs f, and how oncolytic viruses and modified immune environments might bring TILs to more resistant cancers such as pancreatic and colorectal tumors.
Learn how surgical precision, immunotherapy, and translational research come together to push the boundaries of what's possible in cancer treatment. . Tune in to the full conversation now.
Related Topics
You May Also Like
Carrie Printz
Podcast
Monty Pal
What it Takes to Close the Gap in Pediatric Cancer Care with Leo Wang, M.D., Ph.D.
Podcast
Monty Pal
Reengineering CAR T for Solid Tumors: What Glioblastoma Has Taught Us with Christine Brown, Ph.D.
Article
Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
Press Release
OVN Staff
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
Press Release
OVN Staff